Document is current
Any future updates will be listed below
-
Authors
Grünewald, Julian http://orcid.org/0000-0001-7537-7505
Zhou, Ronghao http://orcid.org/0000-0002-3917-0694
Lareau, Caleb A. http://orcid.org/0000-0003-4179-4807
Garcia, Sara P. http://orcid.org/0000-0003-3312-6454
Iyer, Sowmya
Miller, Bret R. http://orcid.org/0000-0002-9872-4642
Langner, Lukas M. http://orcid.org/0000-0003-4658-9829
Hsu, Jonathan Y.
Aryee, Martin J. http://orcid.org/0000-0002-6848-1344
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
- License Information
-
More Information
Article History
Received: 23 September 2019
Accepted: 23 April 2020
First Online: 1 June 2020
Competing interests
: J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals and Verve Therapeutics (f/k/a Endcadia). M.J.A. has financial interests in Excelsior Genomics. The interests of J.K.J. and M.J.A. were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies. J.K.J. is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.G., R.Z. and J.K.J. are co-inventors on a patent application that has been filed by Partners Healthcare/Massachusetts General Hospital on engineered programmable multi-deaminase base editor architectures to enable concurrent editing of distinct bases on DNA.
